Form 4 for INAB IN8BIO, INC.
Accepted 2024-10-08 00:00:00 ET · period of report 2024-10-04 · accession 0001415889-24-024866 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-10-08 | 2024-10-04 | INAB | Ho William Tai-Wei | Pres AND CEO, Dir, 10% | A - Grant | — | +126.6K | 2.55M | +5% | — |
| DM | 2024-10-08 | 2024-10-04 | INAB | Ho William Tai-Wei | Pres AND CEO, Dir, 10% | A - Grant | — | +208.5K | 126.6K | New | — |
| D | 2024-10-08 | 2024-10-04 | INAB | Ho William Tai-Wei | Pres AND CEO, Dir, 10% | D - Sale to Iss | — | -82.0K | 0 | -100% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-10-04 | A | A | 126,582 | — | 2,548,094 | D | — | — | (F1) The reported securities are included within 126,582 Issuer Units purchased by the Reporting Person for $0.395 per Unit. Each Unit consists of one share of common stock and one Series C warrant representing the right to purchase 126,582 shares of common stock. |
| 2 | Derivative | Series A Warrants (right to buy) | 2024-10-04 | A | A | 81,967 | — | 81,967 | D | $0.45 · — to 2025-10-04 | 81,967 Common Stock | (F3) The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on December 13, 2023 with an exercise price of $1.25 and expiration date of June 13, 2025. The exercise price was reduced to $0.45 and the warrant expiration date was extended to October 4, 2025. (F5) The reported securities are included within 81,967 Issuer Units purchased by the Reporting Person for $1.22 per Unit. Each Unit consists of one share of common stock, one Series A warrant and one Series B warrant, each warrant represents the right to purchase 81,967 shares of common stock. (F4) Fully vested and exercisable. |
| 3 | Derivative | Series A Warrants (right to buy) | 2024-10-04 | D | D | 81,967 | — | 0 | D | $1.25 · — to 2025-06-13 | 81,967 Common Stock | (F3) The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on December 13, 2023 with an exercise price of $1.25 and expiration date of June 13, 2025. The exercise price was reduced to $0.45 and the warrant expiration date was extended to October 4, 2025. (F5) The reported securities are included within 81,967 Issuer Units purchased by the Reporting Person for $1.22 per Unit. Each Unit consists of one share of common stock, one Series A warrant and one Series B warrant, each warrant represents the right to purchase 81,967 shares of common stock. (F4) Fully vested and exercisable. |
| 4 | Derivative | Series C Warrants (right to buy) | 2024-10-04 | A | A | 126,582 | — | 126,582 | D | $0.27 · — to 2027-10-04 | 126,582 Common Stock | (F1) The reported securities are included within 126,582 Issuer Units purchased by the Reporting Person for $0.395 per Unit. Each Unit consists of one share of common stock and one Series C warrant representing the right to purchase 126,582 shares of common stock. (F4) Fully vested and exercisable. |